Acetaminophen News and Research

RSS
The pain-reliever acetaminophen (also known as paracetomol) is one of the best-selling over-the-counter medications, used by more than 200 million Americans a year. It is sold under many brand names, including Tylenol, and is an ingredient in nearly 200 medications, both over-the-counter (such as Excedrin, Midol, NyQuil, and Sudafed) and prescription (such as Vicodin).
Labopharm prices underwritten public offering of 11.7M units

Labopharm prices underwritten public offering of 11.7M units

New pain management options for patients undergoing knee or hip replacements

New pain management options for patients undergoing knee or hip replacements

Labopharm begins proposed public offering of common stock

Labopharm begins proposed public offering of common stock

Cadence Pharmaceuticals' IV acetaminophen NDA receives FDA Complete Response letter

Cadence Pharmaceuticals' IV acetaminophen NDA receives FDA Complete Response letter

QRxPharma announces the initiation of second pivotal Phase 3 registration trial of MoxDuo IR

QRxPharma announces the initiation of second pivotal Phase 3 registration trial of MoxDuo IR

Doctors do not follow evidence-based guidelines for treating low back pain, says report

Doctors do not follow evidence-based guidelines for treating low back pain, says report

Study indicates pain treatment may vary in Latino and white children post surgery

Study indicates pain treatment may vary in Latino and white children post surgery

Positive data from Cara Therapeutics' peripherally-restricted kappa opioid agonist Phase II trial

Positive data from Cara Therapeutics' peripherally-restricted kappa opioid agonist Phase II trial

FDA approves Amneal Pharmaceuticals' Tramadol/APAP tablets

FDA approves Amneal Pharmaceuticals' Tramadol/APAP tablets

Children exposed to acetaminophen prenatally more likely to have asthma symptoms at age five

Children exposed to acetaminophen prenatally more likely to have asthma symptoms at age five

FDA approves Labopharm's OLEPTRO antidepressant for MDD

FDA approves Labopharm's OLEPTRO antidepressant for MDD

Depomed receives second $500,000 milestone payment from Covidien

Depomed receives second $500,000 milestone payment from Covidien

New analysis reveals high rates of CNS disorders in autistic children

New analysis reveals high rates of CNS disorders in autistic children

Safety concerns of acetaminophen

Safety concerns of acetaminophen

Labopharm settles $1 million standby equity distribution with YA Global Master SPV

Labopharm settles $1 million standby equity distribution with YA Global Master SPV

Woodcock discusses FDA's ongoing initiative to reduce preventable harm from medication use

Woodcock discusses FDA's ongoing initiative to reduce preventable harm from medication use

Labopharm intends to draw down $1 million on SEDA; issues discount shares to YA Global Master

Labopharm intends to draw down $1 million on SEDA; issues discount shares to YA Global Master

MSD to distribute and market Labopharm's Tradorec XL in the U.K.

MSD to distribute and market Labopharm's Tradorec XL in the U.K.

Fitch Ratings announces Covidien rating outlook stable

Fitch Ratings announces Covidien rating outlook stable

CPSC announces voluntary recall of Vicks Dayquil Cold & Flu Liquicaps

CPSC announces voluntary recall of Vicks Dayquil Cold & Flu Liquicaps